Cure HHT

Au revoir from Mandelieu-la-Napoule. The scale of our 15th International HHT Scientific Conference is the result of years of effort to grow the medical and scientific community focusing on this disease. The minds in attendance and the work presented at our four day conference should leave patients everywhere with hope. We are grateful to all those who attended -- but more importantly, for your work and dedication. Much life-saving impact is ahead. Scroll through these images to get a recap from our final day.

Day 3 in France was a particularly impactful day -- a demonstration of the progress we’ve made and the hope that lies just ahead. Notably, Day 3 featured our inaugural conference session of plenary randomized clinical trials – a major milestone and culmination of years of effort. The day also featured a profoundly impactful analysis on the healthcare cost of HHT in the U.S., which is vitally important for our efforts to increase funding and focus on HHT. Click through for more.

And that's a wrap from Day 2 at #HHTSciCon. Our second day in France began with an overview of Diagonal Therapeutics' novel antibody therapy that as the potential to reverse disease at the biologic level and concluded with a "pros & cons" debate session on contentious HHT topics... with plenty of meaningful science and research in between. The future of HHT treatment is bright thanks to the brilliant minds present at this meeting.

Day 1 of #HHTSciCon, in the books -- and what a day it was. Scroll through these images to get a quick recap of a truly transformational and inspiring start to our conference just outside Cannes, France -- which included a presentation many of our long-time attendees dubbed the most transformational ever given. The science shared and debated at this event will lead to the breakthroughs of tomorrow.

A week of progress ahead. We're proud to share we've set a new attendee record for our upcoming International Scientific Conference, and our committed to continuing to grow the medical and science community focusing on this disease. Learn more here: https://lnkd.in/gBJ96geX

Wonderful news to share: the PATH Trial was featured in the NIH Director's blog post! Congratulations to all who worked on this trial! The awareness and accomplishment cannot be understated! #NIH #Rarediseaseresearch #clinical trials.   https://lnkd.in/eBbJ9bZr

The HHT Continuing Education Program is a free program dedicated to providing HHT education to healthcare providers. Explore the comprehensive course catalog that covers the latest in HHT screening, treatment and management: https://lnkd.in/gx9YgauG To this day, the average delay of diagnosis is 27 years from onset of first symptoms. Sharing information about the HHT Continuing Education Program within your networks and institutions helps prevent needless tragedies. Share the HHT Continuing Education Program flyer with your colleagues today: https://lnkd.in/gen4px5w

Thrilled to have Diagonal Therapeutics' leadership speaking at our upcoming Scientific Conference -- and more importantly, thankful for the groundbreaking work their team is pursuing.

Our upcoming 15th International HHT Scientific Conference is a global affair, as we're excited to share that researchers and clinicians from over 26 countries will be joining us! This conference marks a significant milestone in our journey to foster research and collaboration in the HHT community. Together, we’ve built a thriving network dedicated to advancing understanding and treatment. Life-changing impact will come out of this meeting in just a few weeks. You can learn more about the program here: https://lnkd.in/gBJ96geX